How Advocacy Groups, Biosimilar Makers Can Improve Biologics Education For Physicians
How Advocacy Groups, Biosimilar Makers Can Improve Biologics Education For Physicians

In this first of two articles, an advocate from the Crohn's and Colitis Foundation shares details about the Foundation’s ongoing initiatives in terms of educating physicians, as well as what can be done to better understand and improve physicians’ biologics and biosimilar prescribing practices.    

  • 3 Crucial Discussions From The Biosimilar Medicines Conference
    3 Crucial Discussions From The Biosimilar Medicines Conference

    After roughly four years of writing about biosimilars, I can finally say I attended the Annual Biosimilar Medicines Conference. This conference was valuable to get a closer look at Europe as well, not only to see where things are working, but also where they're not.

  • Biosimilars In The Hospital Market, Then And Now: Addressing The Challenges
    Biosimilars In The Hospital Market, Then And Now: Addressing The Challenges

    About 12 years ago, while working at a group purchasing organization (GPO), I had my first conversations with pharma/biotech companies about the possibility of developing and launching biosimilar drugs. Part of my role at the GPO was related to tracking and commenting on policies CMS and the FDA were developing.

  • Translating Patient And Physician Needs Into Biosimilar Education
    Translating Patient And Physician Needs Into Biosimilar Education

    As we see more real-world evidence (RWE) released in the gastroenterology community, I wanted to learn how one patient advocacy organization is approaching biosimilar education, what challenges the organization is facing, and how the industry and FDA can better reach patients and physicians.

  • What’s In A Name? FDA Proposes Updates To Its Biosimilar Naming Policy
    What’s In A Name? FDA Proposes Updates To Its Biosimilar Naming Policy

    The U.S. FDA issued an updated draft guidance on March 7 on the nonproprietary naming of biologics, titled Nonproprietary Naming of Biological Products: Update (“guidance”). This update is the FDA’s second attempt at a policy for nonproprietary name suffixes for biologic products. It also highlights the perceived tension between the FDA’s pharmacovigilance role and its goal of increasing the availability of biosimilars. At least for this round, the FDA’s interest in tracking pharmacovigilance data seems to have received priority.

  • Top 4 Takeaways From The BioTech Pharma Summit
    Top 4 Takeaways From The BioTech Pharma Summit

    Last week, I had the pleasure of chairing the first day of the BioTech Pharma Summit: Biologics and Biosimilars conference in the gorgeous Porto, Portugal. (Don’t ask me how much I spent I spent on port wine in the days before the conference.) The conference was — shockingly — the first European biosimilar conference I have attended in my tenure as a biosimilars editor. (Even though Europe is leaps and bounds — and then more bounds — ahead of the U.S. with biosimilars.)

  • Will PBM Transparency Help Biosimilar Utilization?
    Will PBM Transparency Help Biosimilar Utilization?

    With the list price of newer drugs rising, policy makers are continuing to debate the cost savings biosimilar medications may offer. To date there are 17 FDA-approved biosimilars targeting various disease states. While biosimilars could slow the dramatic rise in the overall drug spend, many questions about them remain such as litigation, interchangeability, and how they will be integrated into the market. The last question is the most intriguing, and it is heavily dependent on the decision of pharmacy benefit managers (PBMs) about their formularies.

  • Biosimilars And The Site Of Care: Current Considerations
    Biosimilars And The Site Of Care: Current Considerations

    At the CBI Biosimilars Summit in January, I had the pleasure of moderating a panel comprising three experts, including Jesse Peterson, clinical development manager at Fairview Specialty Pharmacy. The topic of conversation was stakeholder education, which Peterson is well-equipped to speak about, given his position at regional specialty pharmacy. In his role, Peterson works with experts across the pharmacy operations team and manages relationships with the health system’s payer partners and manufacturers. He is responsible for sharing updates on the future of the specialty pipeline internally and with payers, as well as identifying areas where potential savings could be realized.

  • How Can Manufacturers, Oncologists Prepare For The Oncology Biosimilar Boom?
    How Can Manufacturers, Oncologists Prepare For The Oncology Biosimilar Boom?

    A few months ago, I read a fabulous Q&A in Managed Care Magazine featuring oncologist Gary Lyman and co-director of the Hutchinson Institute for Cancer Outcomes Research at the Fred Hutchinson Cancer Research Center. In this day and age, we regularly come across surveys or discussions emphasizing how much more work we have to do in the education realm to ensure physicians’ comfort with biosimilars. But after reading Lyman’s interview on one cold, dreary January day, I felt buoyed. That’s not to say there isn’t more work to be done, of course. But it was reassuring to see a prominent member of the oncology community express such comfort and confidence in biosimilars.

  • Biosimilars And The BPCIA: Past, Present, And Future
    Biosimilars And The BPCIA: Past, Present, And Future

    While the biosimilar market in the U.S. has gotten off to a relatively slow start compared to Europe, where biosimilars have been available since 2006, it has recently gained momentum and will continue to grow in the coming years as more “blockbuster” biologics lose regulatory exclusivity and patent protection. Here we review our observations in the biosimilar space since the enactment of the 2009 Biologics Price Competition and Innovation Act (BPCIA) and our view of the future of biosimilars and related patent disputes.

More Biosimilar editorial...

BIOSIMILAR INSIGHTS

More From Biosimilar...

TRAINING COURSES

The MHRA Data Integrity Guidance Clarified: What it Means for Industry & Patients April 24 - 24, 2019
1:00 PM - 2:30 PM EDT
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Essentials of Disinfectant Efficacy Testing – Ensuring Microbial Control April 25 - 25, 2019
1pm-2:30pm EDT, Online Training
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Preparing eCTD Submissions: A Step-By-Step Guide April 29 - 29, 2019
1pm-2:30pm EST, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Implementing a Robust Change Control Program – Key Elements for Process and Documentation Compliance May 6 - 6, 2019
1pm-2:30pm EDT, Online Training
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Critical Thinking In Clinical Research – A Better Way May 7, 2019
11am-12:00pm EDT, Online Training
Duration:  60 minutes
Price:  Free Course - Includes bonus handouts!
Biosimilars Commercialisation Summit 2019 May 14 - 16, 2019
Amsterdam
New FDA Draft Guidance – A Risk-Based Approach to Monitoring of Clinical Investigations May 14 - 14, 2019
Online Training; 1:00 - 2:30 PM EDT US
Duration:  60 minutes
Price:  $299 - Includes Bonus Handouts!
ICH E6 Addendum R2 Team Training and Action Planning May 21 - 21, 2019
11am-12:30pm EST, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Writing Effective 483 and Warning Letter Responses May 23 - 23, 2019
1pm-2:30pm EDT, Online Training
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
DIA 2019 Global Annual Meeting June 23 - 27, 2019
San Diego, CA
More Upcoming Courses
Anna Rose Welch article header

 EVENTS

The MHRA Data Integrity Guidance Clarified: What it Means for Industry & Patients April 24 - 24, 2019
1:00 PM - 2:30 PM EDT
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Essentials of Disinfectant Efficacy Testing – Ensuring Microbial Control April 25 - 25, 2019
1pm-2:30pm EDT, Online Training
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Preparing eCTD Submissions: A Step-By-Step Guide April 29 - 29, 2019
1pm-2:30pm EST, Online Training
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!
Implementing a Robust Change Control Program – Key Elements for Process and Documentation Compliance May 6 - 6, 2019
1pm-2:30pm EDT, Online Training
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Critical Thinking In Clinical Research – A Better Way May 7, 2019
11am-12:00pm EDT, Online Training
Duration:  60 minutes
Price:  Free Course - Includes bonus handouts!

LIFE SCIENCE EVENTS

Essentials of Disinfectant Efficacy Testing – Ensuring Microbial Control April 25 - 25, 2019
1pm-2:30pm EDT, Online Training
Preparing eCTD Submissions: A Step-By-Step Guide April 29 - 29, 2019
1pm-2:30pm EST, Online Training
Critical Thinking In Clinical Research – A Better Way May 7, 2019
11am-12:00pm EDT, Online Training
More Events...

LIFE SCIENCE INDUSTRY EVENTS

Essentials of Disinfectant Efficacy Testing – Ensuring Microbial Control April 25 - 25, 2019
1pm-2:30pm EDT, Online Training
Preparing eCTD Submissions: A Step-By-Step Guide April 29 - 29, 2019
1pm-2:30pm EST, Online Training
Critical Thinking In Clinical Research – A Better Way May 7, 2019
11am-12:00pm EDT, Online Training
More Industry Events

ABOUT BIOSIMILAR DEVELOPMENT

Biosimilar Development is dedicated to presenting technical information, thought leadership, and commentary for the biosimilar development and manufacturing community. On this site, users will find exclusive and actionable content on the industry trends and challenges affecting the emerging biosimilars market. Browse our articles, case studies, and white papers on topics related to biosimilar development, manufacturing, quality, distribution, FDA guidance, BPCIA, global markets, government regulations, and intellectual property.

Biosimilar Development is part of the Life Science Connect media group, which strives to facilitate connections and foster collaborations in pharmaceutical development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.